Secukinumab safety and efficacy in JPsA and ERA

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-003761-26

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To demonstrate that the time to flare in Treatment Period 2 is longer with secukinumab for combined ERA and JPsA groups than with placebo.


Critère d'inclusion

  • Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis

Liens